Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 2/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174538 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL12971145 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL9207582 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL4950737 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL5504523 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL3356485 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL11897705 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL9211956 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL5508335 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 | |
| SCHEMBL12971108 | 1.00 | OPRM1 (0.50) | OPRM1SPHK1CYP2D6LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159861-A1 | APJ Receptor Compounds | ANCHOR THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150011466-A1 | APJ Receptor Compounds | ANCHOR THERAPEUTICS INC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20130210709-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| WO-2010053550-A2 | CXCR4 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | OPRM1 1747/4885SPHK1 2743/4885CYP2D6 4079/4885 |
| US-20150011466-A1 | APJ Receptor Compounds | APLNR, AP1G1, AP2B1 | OPRM1 233/4885SPHK1 2187/4885CYP2D6 3976/4885 |
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | OPRM1 223/4885SPHK1 2349/4885CYP2D6 4075/4885 |
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | OPRM1 393/4885SPHK1 461/4885CYP2D6 4390/4885 |
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | CXCR5, CXCR1, CCR5 | OPRM1 1105/4885SPHK1 680/4885CYP2D6 3842/4885 |
| US-20130210709-A1 | CXCR4 Receptor Compounds | CXCR4, CXCL12, SDF4 | OPRM1 124/4885SPHK1 1656/4885CYP2D6 4288/4885 |
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | OPRM1 31/4885SPHK1 2742/4885CYP2D6 3272/4885 |
| US-20160159861-A1 | APJ Receptor Compounds | APLNR, AP1G1, AP2B1 | OPRM1 233/4885SPHK1 2187/4885CYP2D6 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.